ArticleNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2026
Modeling the Impact of Smoking on Mortality in Argentina From 2000 to 2100. A Maximum Potential Reduction in Premature Mortality Analysis.
Article in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lung Cancer Screening-Eligible Population From 2000 to 2050 in Argentina: A Simulation Study Brief Report.JTO clinical and research reports · 2026Article
- Benefits and harms of lung cancer screening strategies in Argentina: a modeling study.Lancet regional health. Americas · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionIn Argentina, 23% of adults smoke; the future burden of smoking on mortality in the country is unknown. We estimate future smoking-attributable mortality if current smoking trends continue and compare this with an ideal scenario in which all smoking ceases in 2024. AIMS AND
methodsWe developed a discrete deterministic compartmental simulation model of cigarette smoking by birth cohort in Argentina. The model was validated against observed sex-specific adult smoking prevalence. We then simulated smoking prevalence, smoking-attributable deaths (SADs), and life-years lost (LYL) from 2000 to 2100 under a Status Quo scenario, where future smoking prevalence follows current trends. Additionally, we modeled an ideal scenario where all smoking ceases starting in 2024. We calculated the Maximum Potential Reduction in Premature Mortality (MPRPM) as the LYL difference between the two scenarios from 2024 to 2100.
resultsThe model adequately reproduces observed smoking prevalence in Argentina. Approximately 55,700 SADs are estimated to occur in 2024. Under the Status Quo, over 4 million deaths due to smoking and around 79 million LYL would occur from 2000 to 2100. If all smoking had ceased in 2024, 49 million LYL due to smoking would still occur, resulting in an MPRPM of 30 million years, about 38% of the expected burden.
conclusionsArgentina faces a significant smoking-attributable mortality burden this century, with a substantial portion already unavoidable due to past smoking. Further tobacco control interventions, however, could still considerably reduce premature deaths and years of life lost. Prompt action is needed to realize these potential health gains. IMPLICATIONS: This modeling study provides an estimation of the future burden of smoking-attributable mortality in Argentina and highlights the maximum potential health benefits if all smoking would cease by 2024. While a portion of smoking-related mortality is unavoidable due to past smoking, the results show that further tobacco control interventions could still prevent a substantial number of premature deaths and life-years lost. These findings underscore the need for continued public health efforts to reduce smoking rates and mitigate its long-term effects on population health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.